BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439
186 results:

  • 1. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma.
    Patiño-García A; Guruceaga E; Andueza MP; Ocón M; Fodop Sokoudjou JJ; de Villalonga Zornoza N; Alkorta-Aranburu G; Uria IT; Gurpide A; Camps C; Jantus-Lewintre E; Navamuel-Andueza M; Sanmamed MF; Melero I; Elgendy M; Fusco JP; Zulueta JJ; de-Torres JP; Bastarrika G; Seijo L; Pio R; Montuenga LM; Hernáez M; Ochoa I; Perez-Gracia JL
    EBioMedicine; 2024 Apr; 102():105048. PubMed ID: 38484556
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary cancer.
    Chinchilla-Tábora LM; Montero JC; Corchete LA; González-Morais I; Del Barco Morillo E; Olivares-Hernández A; Rodríguez González M; Sayagués JM; Ludeña MD
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396726
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A Single-Center Analysis of How HLA Mismatch and Donor-Specific Antibodies Affect Short-Term Outcome After lung Transplantation: A Pilot Study Before a Country-Wide Histocompatibility Study in Japan.
    Hirama T; Akiba M; Watanabe T; Watanabe Y; Oishi H; Okada Y
    Transplant Proc; 2024 Mar; 56(2):363-368. PubMed ID: 38320866
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The novel hla-a*11:01:124 allele was identified in a Chinese individual.
    Hao Q; Wang Y; Ren Z; Xu H; Zhang Y
    HLA; 2024 Jan; 103(1):e15296. PubMed ID: 38192173
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. HER2 and hla-a*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity.
    Bassan D; Weinberger L; Yi J; Kim T; Weist MR; Adams GB; Foord O; Chaim N; Tabak S; Bujanover N; Lopesco Y; Vucci K; Schnair C; Levy-Knafo L; Kendall RL; Calzone FJ; Sharbi-Yunger A
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097342
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines.
    Dhall A; Patiyal S; Kaur H; Raghava GPS
    Comput Biol Med; 2023 Dec; 167():107594. PubMed ID: 37918263
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Over-representation analysis of angiogenic factors in immunosuppressive mechanisms in neoplasms and neurological conditions during COVID-19.
    Chatterjee S; Sanjeev BS
    Microb Pathog; 2023 Dec; 185():106386. PubMed ID: 37865274
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Early protective effect of a ("pan") coronavirus vaccine (PanCoVac) in Roborovski dwarf hamsters after single-low dose intranasal administration.
    Abdelaziz MO; Raftery MJ; Weihs J; Bielawski O; Edel R; Köppke J; Vladimirova D; Adler JM; Firsching T; Voß A; Gruber AD; Hummel LV; Fernandez Munoz I; Müller-Marquardt F; Willimsky G; Elleboudy NS; Trimpert J; Schönrich G
    Front Immunol; 2023; 14():1166765. PubMed ID: 37520530
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer.
    Mota I; Patrucco E; Mastini C; Mahadevan NR; Thai TC; Bergaggio E; Cheong TC; Leonardi G; Karaca-Atabay E; Campisi M; Poggio T; Menotti M; Ambrogio C; Longo DL; Klaeger S; Keshishian H; Sztupinszki ZM; Szallasi Z; Keskin DB; Duke-Cohan JS; Reinhold B; Carr SA; Wu CJ; Moynihan KD; Irvine DJ; Barbie DA; Reinherz EL; Voena C; Awad MM; Blasco RB; Chiarle R
    Nat Cancer; 2023 Jul; 4(7):1016-1035. PubMed ID: 37430060
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
    Bolaños-Meade J; Hamadani M; Wu J; Al Malki MM; Martens MJ; Runaas L; Elmariah H; Rezvani AR; Gooptu M; Larkin KT; Shaffer BC; El Jurdi N; Loren AW; Solh M; Hall AC; Alousi AM; Jamy OH; Perales MA; Yao JM; Applegate K; Bhatt AS; Kean LS; Efebera YA; Reshef R; Clark W; DiFronzo NL; Leifer E; Horowitz MM; Jones RJ; Holtan SG;
    N Engl J Med; 2023 Jun; 388(25):2338-2348. PubMed ID: 37342922
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
    Chervin AS; Stone JD; Konieczna I; Calabrese KM; Wang N; Haribhai D; Dong F; White MK; Rodriguez LE; Bukofzer GT; Ellis PA; Cosgrove C; Hecquet C; Clarin JD; Palma JP; Reilly EB
    Mol Cancer Ther; 2023 Aug; 22(8):903-912. PubMed ID: 37294945
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Frequency changes in HLA-I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD-L1 expression.
    Wu X; Wang H; Xue F; Jiang T; Chen N; Wang T; Zhang Y; Zhang G; Fu J; Wu Q
    Thorac Cancer; 2023 Jul; 14(20):1932-1940. PubMed ID: 37246469
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Autologous T cell therapy for MAGE-A4
    Hong DS; Van Tine BA; Biswas S; McAlpine C; Johnson ML; Olszanski AJ; Clarke JM; Araujo D; Blumenschein GR; Kebriaei P; Lin Q; Tipping AJ; Sanderson JP; Wang R; Trivedi T; Annareddy T; Bai J; Rafail S; Sun A; Fernandes L; Navenot JM; Bushman FD; Everett JK; Karadeniz D; Broad R; Isabelle M; Naidoo R; Bath N; Betts G; Wolchinsky Z; Batrakou DG; Van Winkle E; Elefant E; Ghobadi A; Cashen A; Grand'Maison A; McCarthy P; Fracasso PM; Norry E; Williams D; Druta M; Liebner DA; Odunsi K; Butler MO
    Nat Med; 2023 Jan; 29(1):104-114. PubMed ID: 36624315
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. An
    Lin J; Liu J; Hao SG; Lan B; Zheng XB; Xiong JN; Zhang YQ; Gao X; Chen CB; Chen L; Huang YF; Luo H; Yi YT; Yi X; Lu JP; Zheng XW; Chen G; Wang XF; Chen Y
    Front Immunol; 2022; 13():1022598. PubMed ID: 36505399
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy.
    Hattori T; Maso L; Araki KY; Koide A; Hayman J; Akkapeddi P; Bang I; Neel BG; Koide S
    Cancer Discov; 2023 Jan; 13(1):132-145. PubMed ID: 36250888
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Therapeutic high affinity T cell receptor targeting a KRAS
    Poole A; Karuppiah V; Hartt A; Haidar JN; Moureau S; Dobrzycki T; Hayes C; Rowley C; Dias J; Harper S; Barnbrook K; Hock M; Coles C; Yang W; Aleksic M; Lin AB; Robinson R; Dukes JD; Liddy N; Van der Kamp M; Plowman GD; Vuidepot A; Cole DK; Whale AD; Chillakuri C
    Nat Commun; 2022 Sep; 13(1):5333. PubMed ID: 36088370
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.
    Kim GB; Fritsche J; Bunk S; Mahr A; Unverdorben F; Tosh K; Kong H; Maldini CR; Lau C; Srivatsa S; Jiang S; Glover J; Dopkin D; Zhang CX; Schuster H; Kowalewski DJ; Goldfinger V; Ott M; Fuhrmann D; Baues M; Boesmueller H; Schraeder C; Schimmack G; Song C; Hoffgaard F; Roemer M; Tsou CC; Hofmann M; Treiber T; Hutt M; Alten L; Jaworski M; Alpert A; Missel S; Reinhardt C; Singh H; Schoor O; Walter S; Wagner C; Maurer D; Weinschenk T; Riley JL
    Sci Transl Med; 2022 Aug; 14(660):eabo6135. PubMed ID: 36044599
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Application of real-time MRI-guided linear accelerator in stereotactic ablative body radiotherapy for non-small cell lung cancer: one step forward to precise targeting.
    Kang HJ; Kwak YK; Kim M; Lee SJ
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3215-3223. PubMed ID: 36040666
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Conditional Survival of Patients With Extracranial Oligometastatic Treated With Stereotactic Body Radiation Therapy: An International Consortium Study.
    Chen H; Badellino S; Biswas T; Dagan R; Erler D; Foote M; Poon I; Redmond KJ; Ricardi U; Sahgal A; Louie AV
    Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):902-909. PubMed ID: 35753554
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells.
    Tokatlian T; Asuelime GE; Mock JY; DiAndreth B; Sharma S; Toledo Warshaviak D; Daris ME; Bolanos K; Luna BL; Naradikian MS; Deshmukh K; Hamburger AE; Kamb A
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091455
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 10.